Loading the comparison…
Loading the comparison…
Any covered state and procedure, side by side
| Tumor & fibroid embolization · Texas | Tumor & fibroid embolization · Florida | |
|---|---|---|
| Surgeons, 2024 | 20 | 29 |
| Medicare fee-for-service cases | 1,239 | 1,301 |
| Growth since 2019 (Medicare FFS) | +2.9%/yr | +2.9%/yr |
| Forecast cases (Medicare FFS) | 3,140 in 2030 | 3,590 in 2030 |
| Forecast growth | +17%/yr to 2030 | +18%/yr to 2030 |
| Per 1,000 Medicare beneficiaries | 0.6 | 0.6 |
| Medicare Advantage share | 59% | 60% |
| Out of hospital | 63% (+61 pts since 2019) | 55% (+45 pts since 2019) |
| Cases per surgeon | 62 | 45 |
| Top 10 surgeons' share | 76% | 63% |
| Surgeons growing | 1 | 3 |
| New since the base year | 3 | 6 |
| Likely to stop billing it | 5 by 2026 | 8 by 2026 |
| Forecast miss, 1 year (procedure) | 11% | 11% |
| Company payments per surgeon | $50K | $57K |
The counts above are the surgeons MedaRep names: who is growing, who is new, who is likely to stop and which companies engage them.